RT Journal Article
SR Electronic
T1 Genome-wide analysis of individual coding variants and HLA-II-associated self-immunopeptidomes in ulcerative colitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.22.23286498
DO 10.1101/2023.03.22.23286498
A1 Wendorff, Mareike
A1 ElAbd, Hesham
A1 Degenhardt, Frauke
A1 Höppner, Marc
A1 Uellendahl-Werth, Florian
A1 Wacker, Eike M.
A1 Wienbrandt, Lars
A1 Juzenas, Simonas
A1 Regeneron Genetic Center
A1 Koudelka, Tomas
A1 Ellinghaus, David
A1 Bacher, Petra
A1 Tholey, Andreas
A1 Laudes, Matthias
A1 Ziemann, Malte
A1 Bokemeyer, Bernd
A1 Schreiber, Stefan
A1 Lenz, Tobias L.
A1 Franke, Andre
YR 2023
UL http://medrxiv.org/content/early/2023/05/17/2023.03.22.23286498.abstract
AB Genome wide association studies contributed to a better understanding of the etiology of inflammatory bowel disease (IBD). While over 240 genetic associations with IBD have since been identified, functional follow-up studies are still in their infancy with the overall pathogenesis of IBD remaining unsolved. E.g., a functional understanding of the genetic association between the human leukocyte antigen (HLA) region and ulcerative colitis (UC) – one subtypes of IBD – is still lacking. Here, we analyzed whether an autoimmune reaction involving the HLA class II proteins HLA-DQ and -DR, both being strongly associated with UC, could be a disease trigger or driver. To this end, genotype data derived from whole exome sequencing and genome-wide SNP array data of 863 German UC patients as well as 4,185 healthy controls were analyzed. Association analyses identified novel variants in the NOD2 and SNX20 genes to be linked with UC and confirmed known HLA allele associations. Employing the genetic data, we generated patient-specific self-immunopeptidomes and in silico predicted HLA-peptide binding. Peptidome-wide association analyses of peptide binding preferences in a set of candidate proteins yielded significant associations with 234 specific peptides. Interestingly, none of those peptides showed a differential presence in case and control samples. The disease-associated candidate peptides predicted to be presented by risk HLA proteins contained predominantly aromatic amino acids. In contrast, protective HLA proteins were predicted to bind peptides enriched in acidic amino acids. In summary, we present a proof-of-concept immunogenetic analysis that contributes to a better understanding of the HLA in UC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.W. and H.E. were funded by the German Research Foundation (DFG) (Research Training Group 1743, Genes, Environment and Inflammation). T.L.L. was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - 437857095. The study received infrastructure support from the DFG Cluster of Excellence 2167 Precision Medicine in Chronic Inflammation (PMI) (EXC 2167-390884018). The funding agency had neither a role in the design, collection, analysis, and interpretation of data nor in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University Hospital Schleswig-Holstein (UKSH) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.